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Highlights: 
 Axonal excitability and its correlation with serum VEGF and nerve edema detected 
by ultrasound were studied in POEMS syndrome. 
 Excitability testing showed altered sodium, potassium, and inward rectifying corrents, 
some of which were correlated with VEGF levels and nerve edema. 
 In addition to structural changes (demyelination), nerve edema induced by 
upregulated VEGF, and upregulated inflammatory cytokines can modulate profiles of 
POEMS neuropathy. 
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Abstract: 
Objective: POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and 
skin changes) syndrome is a rare cause of demyelinating neuropathy with upregulation 
of vascular endothelial growth factor (VEGF). This study aimed to elucidate axonal 
excitability properties and their relation to VEGF levels and nerve edema in POEMS 
neuropathy. 
Methods: Axonal excitability measurement and nerve ultrasound were performed in 
the median nerve of 33 patients with POEMS syndrome. Serum VEGF levels were 
measured by ELISA. 
Results: Compared with normal subjects (n=87), POEMS patients showed longer 
strength-duration time constant, fanning-out of threshold electrotonus curves, and 
greater threshold changes in a hyperpolarizing current-threshold relationship. Nerve 
ultrasound showed significant enlargement in POEMS patients. Serum VEGF levels and 
the extent of nerve edema partly correlated with nerve conduction slowing, as well as 
persistent sodium currents and inward rectification. 
Conclusions: In POEMS syndrome, patterns of changes in excitability properties 
could suggest increased persistent sodium currents, and impaired potassium and inward 
rectifying channels. The findings were not consistent with depolarization due to nerve 
edema and compression ischaemia. 
Significance: In addition to demyelination, nerve edema induced by upregulated 
VEGF, and upregulated inflammatory cytokines could modulate profiles of POEMS 
neuropathy. 
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1. Introduction 
POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) 
syndrome is a rare cause of demyelinating polyneuropathy associated with monoclonal 
plasma cell proliferation and multi-organ involvement (Bardwick et al., 1980; Kuwabara 
et al., 2008a; Dispenzieri, 2014). Serum levels of vascular endothelial growth factor 
(VEGF) are markedly increased in POEMS syndrome, and increased vascular 
permeability and neovasculization mediated by VEGF are likely to cause characteristic 
symptoms such as edema, pleural effusion/ascites, organomegaly and skin angiomata 
(Watanabe et al., 1996). However, mechanisms for neuropathy in POEMS syndrome 
have not yet been elucidated, whereas pathological studies have shown perineurial 
edema, and segmental demyelination with uncompacted myelin and secondary axonal 
degeneration (Kanda, 2013). 
The proposed mechanisms for POEMS neuropathy include that the combination of 
blood-nerve barrier breakdown by VEGF and following invasion of other inflammatory 
cytokines such as interleukin-12, and tumor necrosis-causes nerve demyelination 
(Kanai et al., 2012), and that nerve edema mediated by VEGF leads to compression 
ischaemia and axonal depolarization (Kanda, 2013), but these hypotheses still need 
confirmation. 
Axonal excitability testing using threshold tracking was developed to investigate ion 
channel function, membrane potential, and passive membrane properties of human 
axons in vivo (Bostock et al., 1998; Burke et al., 2001), and over the past two decades, 
the technique has been extensively applied to the study of the biophysical properties of 
human peripheral nerves and have provided important insights into axonal ion channel 
function in health and disease (Nodera and Kaji, 2006; Sawai et al., 2008). 
Separately, nerve ultrasound are also becoming increasingly important in the 
diagnosis and evaluation of peripheral neuropathies particularly in the 2000’s (Padua et 
al., 2012) providing new insights into macroscopic nerve morphology. In this study, we 
aimed to elucidate axonal excitability properties and their relation to nerve morphology 
and serum VEGF levels in patients with POEMS syndrome. 
 
2. Methods 
2.1. Subjects 
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This study prospectively enrolled 33 consecutive patients (25 men; age range 36–75 
years, mean 55 years) with newly diagnosed POEMS syndrome, who fulfilled published 
criteria (Kuwabara et al., 2008a) seen at a single tertiary hospital (Chiba University 
Hospital) in Japan from January 2012 to September 2014. We excluded patients with 
renal failure because serum K+ levels can significantly alter membrane potential and 
axonal excitability properties (Kiernan et al., 2000). 
Normal control data for axonal excitability testing were obtained from 87 
age-matched healthy subjects (49 men; age range 38–76 years, mean 56 years). Serum 
VEGF levels were measured by ELISA commercially (Special Reference Laboratory Co. 
Ltd., Tokyo, Japan). All the patients and normal control subjects gave informed consent 
to the study procedures, which was approved by the Ethics Committee of Chiba 
University Graduate School of Medicine. 
 
2.2. Neurophysiological assessment 
Neurophysiological evaluation was performed before thalidomide treatment, and in 9 
patients, follow-up studies were done 3 months later. Nerve conduction studies were 
conducted using conventional procedures and a standard electromyography machine 
(Viking 4, Nicolet Biomedical Japan, Tokyo, Japan). Nerve excitability testing was 
performed on the median nerve at the wrist (3 cm proximal to the wrist crease) using a 
computerized program (QTRAC® with multiple excitability protocol, TRONDNF, Institute 
of Neurology, London, UK) as described previously (Kiernan et al., 2000; Nasu et al., 
2014). Compound muscle action potentials (CMAPs) were recorded from the abductor 
pollicis brevis. Skin temperature was measured near the stimulating site and maintained 
above 32.0°C (using extra heating, if necessary). Excitability indices included strength–
duration time constant, threshold electrotonus, and refractoriness, supernormality, and 
late subnormality of the recovery cycle of axonal excitability with a single supramaximal 
conditioning stimulus, and a current-threshold relationship. 
 
2.3. Nerve ultrasound 
Ultrasound examination was performed with Logiq E9 (GE Healthcare Japan, Tokyo, 
Japan) with a 6-12MHz electronic linear array probe at the wrist, forearm, and elbow 
portion of the median nerve trunk. Cross-sectional area were measured at the inner 
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border of the thin hyperechoic epineural rim by the continuous tracing technique and the 
average values were calculated after serially measuring three times (Kerasnoudis et al., 
2014). No additional force was applied other than the weight of the transducer and the 
extremities were kept in the neutral position to avoid causing any artificial nerve 
deformity. 
 
2.5. Statistical analysis 
All statistical tests were two-sided. The comparison of paired parameters of nerve 
conduction studies or excitability testing between baseline and the second examination 
was evaluated via the paired t-test with Bonferroni’s correction for multiple testing. 
Regression analysis was performed by Pearson’s correlation coefficient test. All 
statistical analyses were performed using JMP software, version 5.1.1 (SAS Institute, 
Inc., Cary, NC, USA). 
 
3. Results 
3.1. Nerve excitability testing and ultrasound 
Table 1 shows results of nerve conduction studies, and excitability testing. Nerve 
conduction velocities were significantly slowed consistent with primary demyelinating 
neuropathy. In excitability testing, strength-duration time constant was significantly 
longer and current required for produce 50% of the maximal CMAP was greater for 
POEMS patients than for normal controls. In the recovery cycle of axonal excitability, 
POEMS patients had greater superexcitability and smaller late subexcitability. POEMS 
patients showed fanning-out in threshold electrotonus particularly in the hyperpolarizing 
direction, and greater threshold changes to hyperpolarizing currents in current-threshold 
relationships (Figure 1). 
Nerve ultrasonography showed significantly greater cross-sectional area at the wrist, 
forearm, and elbow portion of the median nerve in patients with POEMS syndrome than 
in normal subjects. 
 
3.2. Correlation with serum VEGF levels and nerve enlargement 
Before treatment, serum VEGF levels were greatly increased in all patients with POEMS 
syndrome; the mean value was 5143 pg/ml (normal<1000 pg/ml), ranging from 1080 to 
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16400 pg/ml. Table 2 shows correlation of electrophysiological indices with serum VEGF 
levels and cross-sectional area at the elbow. Higher serum VEGF levels were associated 
with longer distal motor latency, and smaller CMAP amplitude in nerve conduction 
studies, and greater threshold changes to long hyperpolarizing conditioning currents. 
Separately larger cross-sectional area on nerve ultrasound was associated with 
slower nerve conduction velocity, smaller CMAP amplitude, and loner strength-duration 
time constant. Serum VEGF levels and nerve cross-sectional area at the time of 
examination did not show significant correlation. 
 
3.3. Serial changes after treatment 
Sequential examinations on nerve excitability and ultrasound were performed before and 
3 months after thalidomide treatment in 9 patients. Table 3 shows serial changes. Serum 
VEGF levels decreased. Nerve cross-sectional area significantly reduced after treatment, 
suggesting edema was a major cause of nerve enlargement Significant improvement 
was observed in distal latency in nerve conduction studies. In excitability testing, 
superexcitability and and threshold change to 100% hyperpolarizing conditioning 
currents in current-threshold relationship significantly changed towards normal (Figure 
2). 
 
4. Discussion 
Our results show that axonal excitability properties in POEMS neuropathy is 
characterized by prolonged strength-duration time constant, increased superexcitability, 
reduced late subexcitability, fanning-out in threshold electrotonus, and greater threshold 
changes to 100% hyperpolarizing conditioning current in current-threshold relationships. 
These findings could suggest altered nodal persistent sodium currents, reduced 
potassium and inward rectifying conductances,respectively (Burke et al., 2001; Nodera 
and Kaji, 2006; Howells et al., 2012). However, their interpretations are difficult because 
of multiple factors such as segmental demyelination, nerve edema, and upregulated 
inflammatory cytokines could contribute to altered channel function. The excitability 
indices and nerve conduction parameters are partly correlated with serum VEGF levels 
and the extent of nerve enlargement. 
Pathological studies have shown segmental demyelination and remyelination, 
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uncompacted myelin, and perineirial edema in sural nerve specimen of patients with 
POEMS syndrome (Koike et al., 2008). The short-internode associated with 
remyelination, and altered myelin resistance may affect the input resistance and lead to 
fanning-out in threshold electrotonus, but again other factors could modulate a total 
findings of excitability testing. 
The pattern of excitability changes are different from those in chronic inflammatory 
demyelinating polyneuropathy (CIDP); previous reports on CIDP have shown that 
compared with normal subjects, strength-duration time constant was significantly shorter, 
and in the recovery cycle, CIDP patients had less refractoriness, supernormality and late 
subnormality than healthy controls (Cappelen-Smith et al., 2000; Sung et al., 2004). 
Current-threshold relationships did not show significant changes. Particularly, 
strength-duration time constant and superexcitability change to the opposite direction in 
POEMS syndrome and CIDP. It is important to differentiate the two conditions because 
POEMS syndrome is often misdiagnosed as CIDP (Nasu et al., 2012), but treatments 
are substantially different. In this regard, whether nerve excitability testing is helpful for 
the differential diagnosis of POEMS syndrome and CIDP, needs to be studied in a 
prospective fashion. 
In the present study, serum VEGF levels were invariably elevated in POEMS patients, 
consistent with previous reports (Kuwabara et al., 2008a, 2008b), and correlated, 
although weakly, with distal latency and hyperpolarizing threshold electrotonus and 
current-threshold relationships (Table 2). These findings might not reflect the direct 
effects of VEGF alone, because multiple inflammatory cytokines such as interleukin-12, 
and tumor necrosis-are simultaneously and markedly upregulated in the active phase 
of POEMS syndrome (Kanai et al., 2012), and it is possible such cytokines other than 
VEGF affect ion channel function, although this should be investigated in further studies. 
Nevertheless, increased vascular permeability mediated by VEGF presumably 
responsible for nerve edema, frequently found on pathological examination (Kanda, 
2013). We initially expected membrane depolarization due to edema-induced 
compression ischaemia in POEMS syndrome, and nerve edema detected by ultrasound 
partly correlated with axonal excitability. However, a combination of the nerve excitability 
changes did not support axonal depolarization. Different from an acute 
compression/ischaemia model, compensatory mechanisms in response to 
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depolarization might act, leading to resulted in a steady state during chronic exposure of 
VEGF and nerve edema. Our study did not reach a conclusion on whether membrane 
potential is altered in POEMS syndrome, because multiple factors in POEMS syndrome 
such as demyelination, and cytokine activation would also largely affect membrane 
properties. 
There are several limitations in this study. We could examine sequential changes in a 
small number of patients (n=9) and relatively short period of follow-up (3 months). 
Secondly, both nerve excitability testing and ultrasound works only in the restricted 
portion of the nerve (e.g., superficially located portion of the nerve). Finally, among the 
inflammatory cytokines elevated in POEMS syndrome, only VEGF was measured. The 
effects of cytokines should be evaluated as a network based on measurements of 
multiple cytokines. 
The pathophysiology of POEMS neuropathy is still unclear, and a complex interaction 
of multiple factors could contribute to development of neuropathy in POEMS syndrome. 
Further multidisciplinary approach using electrophysiological, morphological, and 
biochemical methodology would be required to elucidate the pathogenesis of peripheral 
neuropathy in POEMS syndrome, and we would like to do so in future studies. 
Mitsuma et al., p10 
 
 
 
References 
Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell 
dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin 
changes: the POEMS syndrome. Report on two cases and a review of the literature. 
Medicine (Baltimore) 1980;59:311-22. 
Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human 
peripheral nerve. Muscle Nerve 1998;21:137-158. 
Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol 
2001;112:1575-85. 
Cappelen-Smith C, Kuwabara S, Lin CS, Mogyoros I, Burke D. Activity-dependent 
hyperpolarization and conduction block in chronic inflammatory demyelinating 
polyneuropathy. Ann Neurol 2000 Dec;48:826-32. 
Dispenzieri A. POEMS syndrome: 2014 update on diagnosis, risk-stratification, and 
management. Am J Hematol 2014;89:214-23. 
Howells J, Trevillion L, Bostock H, Burke D. The voltage dependence of I(h) in human 
myelinated axons. J Physiol 2012;590:1625-40. 
Kanai K, Sawai S, Sogawa K, Mori M, Misawa S, Shibuya K, et al. Markedly upregulated 
serum interleukin-12 as a novel biomarker in POEMS syndrome. Neurology 
2012;79:575-82. 
Kanda T. Biology of the blood-nerve barrier and its alteration in immune mediated 
neuropathies. J Neurol Neurosurg Psychiatry 2013;84:208-12. 
Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS. Nerve ultrasound 
score in distinguishing chronic from acute inflammatory demyelinating polyneuropathy. 
Clin Neurophysiol 2014;125:635-41. 
Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: 
a new approach in clinical testing. Muscle Nerve 2000;23:399-409. 
Koike H, Iijima M, Mori K, Yamamoto M, Hattori N, Watanabe H, et al. Neuropathic pain 
correlates with myelinated fibre loss and cytokine profile in POEMS syndrome. J 
Neurol Neurosurg Psychiatry 2008;79:1171-9. 
 
 
 
 
 
 
Mitsuma et al., p11 
 
 
 
Kuwabara S, Dispenzieri A, Arimura K, Misawa S, Nakaseko C. Treatment for POEMS 
(polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) 
syndrome. Cochrane Database Syst Rev 2008a Oct 8;(4):CD006828. 
Kuwabara S, Misawa S, Kanai K, Suzuki Y, Kikkawa Y, Sawai S, et al. Neurologic 
improvement after peripheral blood stem cell transplantation in POEMS syndrome. 
Neurology 2008b;71:1691-5. 
Nasu S, Misawa S, Nakaseko C, Shibuya K, Isose S, Sekiguchi Y, et al. 
Bortezomib-induced neuropathy: axonal membrane depolarization precedes 
development of neuropathy. Clin Neurophysiol. 2014;125:381-7. 
Nasu S, Misawa S, Sekiguchi Y, Shibuya K, Kanai K, Fujimaki Y, et al.. Different 
neurological and physiological profiles in POEMS syndrome and chronic inflammatory 
demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2012;83:476-9. 
Nodera H, Kaji R. Nerve excitability testing and its clinical application to neuromuscular 
diseases. Clin Neurophysiol 2006;117:1902-16. 
Padua L, Liotta G, Di Pasquale A, Granata G, Pazzaglia C, Martinoli C, et al. 
Contribution of ultrasound in the assessment of nerve diseases. Eur J Neurol 
2012;19:47-54. 
Sawai S, Kanai K, Nakata M, Hiraga A, Misawa S, Isose S, et al. Changes in excitability 
properties associated with axonal regeneration in human neuropathy and mouse 
Wallerian degeneration. Clin Neurophysiol. 2008;119:1097-105. 
Sung JY, Kuwabara S, Kaji R, Ogawara K, Mori M, Kanai K, et al. Threshold electrotonus 
in chronic inflammatory demyelinating polyneuropathy: correlation with clinical profiles. 
Muscle Nerve 2004;29:28-37. 
Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular 
endothelial growth factor (VEGF) in POEMS syndrome. Lancet 1996;347:702. 
Mitsuma et al., p12 
 
 
 
Table 1. Results of nerve conduction studies, axonal excitability, and ultrasound.
Normal POEMS syndrome P-value
(n=85) (n=31)
 Nerve conduction study
Distal latency (ms) 3.6 (0.4) 5.3 (1.0) <0.0001
CMAP amplitude (mV) 10.8 (1.2) 5.7 (1.0) <0.0001
Conduction velocity (m/s) 57.7 (6.3) 34.2 (6.1) <0.0001
 Nerve excitability testing (n=87) (n=33)
Strength-duration property
Strength-duration time constant (ms) 0.42 (0.008) 0.50 (0.02) 0.0002
Current for 50% CMAP (mA) 4.5 (0.2) 9.6 (0.8) <0.0001
Recovery cycle
Refractorines (2.0 ms) (%) 47.9 (4.5) 38.5 (4.5) 0.06
Superexcitability (6.3 ms) (%) -20.6 (1.3) -26.0 (1.3) 0.04
Late subnormality (42 ms) (%) 18.5 (1.1) 9.2 (0.9) <0.001
Threshold electrotonus
TEd 10-20ms (%) 69.2 (0.6) 70.7 (1.4) 0.3
TEd 90-100ms (%) 46.1 (0.6) 48.4 (1.1) 0.07
TEh 90-100ms (%) -124.4 (2.4) -136.9 (4.7) 0.02
Current threshold relationship 
50% depolarizing current (%) 51.9 (0.9) 56.3 (1.6) 0.02
100% hyperpolarizing current (%) -309.6 (6.1) -350.6 (13.9) 0.01
Hyperpolarizing I/V slope 0.42 (0.01) 0.36 (0.02) 0.01
 Nerve ultrasound
Cross sectional area (n=23) (n=19)
Wrist (cm
2
) 0.07 (0.01) 0.10 (0.02) 0.001
Forearm (cm
2
) 0.06 (0.01) 0.08 (0.02) <0.0001
Elbow (cm
2
) 0.07 (0.01) 0.11 (0.03) <0.0001
Data are given as mean (SEM).
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Table 2. Correlation of electrophysiological index with VEGF and nerve edema
Serum VEGF level Area (Ultrasound)
R
2 P-value* R
2 P-value*
Nerve conduction study
Motor nerve conduction velocity 0.0593 NS 0.389 0.03
Distal latency 0.133 0.04 0.3344 NS
CMAP amplitude 0.2082 0.01 0.2203 0.04
Nerve excitability testing
Stimulus (mA) for 50% max response 0.05 NS 0.1616 NS
Strength-duration time constant (ms) 0.14 NS 0.3211 0.04
Refractoriness at 2 ms (%) 0.0098 NS 0.0241 NS
Superexcitability (%) 0.015 NS 0.0042 NS
Subexcitability (%) 0.0238 NS 0.0372 NS
TEd(10-20ms) 0.0001 NS 0.005 NS
TEd(90-100ms) 0.0164 NS 0.01 NS
TEh(90-100ms) 0.0185 NS 0.0125 NS
TEh(slope 101-140ms) 0.1941 0.01 0.0241 NS
Hyperpol. I/V slope 0.2007 0.03 0.015 NS
Nerve ultrasound (cross-sectional area)
wrist 0.0218 NS
Forearm 0.0987 NS
Elbow 0.0208 NS
*P-value < 0.05, considered as statistically significant; NS, not significant.
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Table 3. Serum VEGF level, electrophysiology, and nerve ultrasound before and after treatment.
Before 3 months P-value
 Serum VEGF (pg/mL) 6061 (1667) 3600 (1406) 0.2
 Nerve conduction study (n=9)
Distal latency (ms) 5.6 (0.5) 5.2 (0.5) 0.01
CMAP amplitude (mV) 5.2 (1.2) 5.1 (1.5) 0.9
Conduction velocity (m/s) 36.2 (3.6) 37.4 (3.4) 0.3
Nerve excitability testing (n=9)
Strength-duration time constant
Strength-duration time constant (ms) 0.49 (0.01) 0.52 (0.04) 0.5
Current for 50% CMAP (mA) 11.3 (1.9) 8.7 (1.3) 0.2
Recovery cycle
Refractoriness (2.5 ms) (%) 16.0 (4.2) 8.4 (6.1) 0.3
Superexcitability (7.9 ms) (%) -27.1 (1.4) -23.5 (1.6) 0.036
Late subnormality (42 ms) (%) 8.8 (1.2) 11.3 (1.7) 0.2
Threshold electrotonus
TEd 10-20ms (%) 74.4 (1.9) 74.8 (2.2) 1.0
TEd 90-100ms (%) 51.5 (2.2) 51.5 (1.9) 1.0
TEh 90-100ms (%) -150.8 (10.4) -154.0 (11.5) 0.8
Current threshold relationship ( I/V)
50% depolarizing current (%) 57.1 (2.0) 56.8 (2.0) 0.8
100% hyperpolarizing current (%) -395.5 (19.6) -331.8 (18.0) 0.006
Hyperpolarizing I/V slope 0.32 (0.01) 0.41 (0.04) 0.03
 Nerve ultrasound (n=13)
Cross sectional area
Wrist (cm
2
) 0.11 (0.03) 0.10 (0.03) 0.02
Forearm (cm
2
) 0.09 (0.02) 0.08 (0.02) 0.18
Elbow (cm
2
) 0.12 (0.03) 0.10 (0.01) 0.01
Data are given as mean (SEM).
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Figure legends 
Figure 1.  
Nerve excitability testing in patients with POEMS syndrome and in age-matched normal 
subjects. A. Strength-duration time constant. B. Recovery cycle of axonal excitability after 
supramaximal conditioning stimulus. C. Threshold electrotonus. D. Current-threshold 
relationship. Open and filled circles indicate normal subjects and POEMS patients 
respectively. Data are given as mean, and error bars indicate standard error.  
 
Figure 2.  
Sequential changes in nerve excitability testing before and 3 months after the start of 
thalidomide or steroid treatment in patients with POEMS syndrome. A. Recovery cycle of 
axonal excitability after supramaximal conditioning stimulus. B. Current-threshold 
relationship. Filled and open circles indicate before and after treatment respectively. Data 
are given as mean, and error bars indicate standard error. 
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